(Q33706972)

28 July 2017

title

Clinical trials, consensus conferences, and clinical practice (English)

1 reference

28 July 2017

A D Sniderman

1

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 July 1999

1 reference

28 July 2017

number of pages

4

1 reference

inferred from page(s)

published in

The Lancet

1 reference

28 July 2017

volume

354

1 reference

28 July 2017

issue

9175

1 reference

28 July 2017

page(s)

327-330

1 reference

Problems in the "evidence" of "evidence-based medicine"

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911185-6

7 January 2021

The philosophical limits of evidence-based medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911185-6

7 January 2021

Source of funding and outcome of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911185-6

7 January 2021

Conflict of interest in the debate over calcium-channel antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911185-6

7 January 2021

Medicolegal implications of the consensus conference, with special attention to the Fifth Antithrombotic Therapy Consensus Conference

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911185-6

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911185-6

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911185-6

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911185-6

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911185-6

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911185-6

7 January 2021

Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911185-6

7 January 2021

Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911185-6

7 January 2021

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911185-6

7 January 2021

Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911185-6

7 January 2021

10.1016/S0140-6736(98)11185-6

Identifiers

DOI

1 reference

28 July 2017

1 reference